Key facts
- It has raised $120.0M across 2 recorded rounds; the latest was Later Stage VC ($75.3M) in Sep 2024.
- Notable investors include Plug and Play Tech Center, Alumni Ventures, GV, Canaan Partners, iSelect Fund — 23 tracked in total.
- Genome Medical has filed 4 Form Ds with the SEC since 2018, most recently Sep 2024 ($75.3M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Genome Medical
Funding rounds
2 roundsAbout Genome Medical
Operator of a genomic medicine delivery company intended to bridge the gap between genome technology and current medical practice. The company connects individuals and health care providers to genetic experts, providing a genetic assessment to individuals regarding the benefits of testing and creating a personalized clinical action plan, enabling patients to make informed treatment decisions at low costs and medical practitioners to accelerate disease diagnosis.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2016
- Employees
- 103
- Website
- genomemedical.com/
- Ownership
- Privately Held (backing)
Genome Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genome Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genome Medical in its N-PORT filings yet. We sweep new filings monthly.